logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

    FiltersReset Filters
    11 results

    • biktarvy

      (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)
      Gilead Sciences, Inc.
      Usage: BIKTARVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg, either as a complete regimen for those with no antiretroviral treatment history or as a replacement for those who are virologically suppressed on a stable regimen without resistance issues.

    • complera

      (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

    • delstrigo

      (doravirine, lamivudine, and tenofovir disoproxil fumarate)
      Merck Sharp & Dohme LLC
      Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

    • descovy

      (emtricitabine and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.

    • dovato

      (dolutegravir sodium and lamivudine)
      ViiV Healthcare Company
      Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

    • genvoya

      (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

    • odefsey

      (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
      Gilead Sciences, Inc.
      Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) as initial therapy for those with no prior treatment and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically-suppressed patients with specific criteria.

    • stribild

      (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
      Gilead Sciences, Inc.
      Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

    • symtuza

      (Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)
      Janssen Products LP
      Usage: SYMTUZA is indicated for treating HIV-1 infection in adults and pediatric patients (≥ 40 kg) with no prior antiretroviral therapy or who are virologically suppressed on a stable regimen for at least 6 months, with no known resistance substitutions.

    • triumeq

      (abacavir sulfate, dolutegravir sodium, lamivudine)
      ViiV Healthcare Company
      Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.